Cision PRWeb / April 20, 2022
AIF Makes Strategic Investment in Cortica
NYSE / April 19, 2022
AIF Rings Closing Bell at New York
Stock Exchange
Latest news
Seed, 2021
diagnosis for
neurodevelopmental
disorders is achievable
with a simple blood test.
AIF is building a world where
Seed, 2021
care for individuals with
disabilities is accessible.
Series A, 2021
therapeutics exist to address
core symptoms of
neurological conditions.
Cision PRWeb / April 20, 2022
AIF makes strategic investment in Cortica...
NYSE / April 19, 2022
AIF rings closing bell at NYSE...
Latest news
Seed, 2021
diagnosis for neurodevelopmental disorders is achievable with a simple blood test
AIF is building a world where
Series C, 2021
microbiome-targeted therapeutics exist to improve nervous system function
Seed, 2021
care for individuals with disabilities is accessible
Series A, 2021
therapeutics exist to address core symptoms of neurological conditions
Seed, 2021
therapy for behavioral conditions is affordable and tech-enabled
Bridge, 2021
where chronic health conditions are manageable through precision nutrition
Growth, 2021
employment opportunities for neurodiverse individuals are plentiful
Strategic, 2022
care for neurological conditions is comprehensive, outcomes-based, and led by doctors
OUR MISSION
AIF’s bold mission is to revolutionize the status quo for diagnosing, treating, and living with autism spectrum disorder (ASD), neurodevelopmental disorders, mental health issues, and complex chronic conditions through a venture capital model that helps accelerate developing and delivering emerging technologies, translational science, and innovative services to empower individuals to reach their full potential.
OUR VISION
We identify unmet needs across the continuum of ASD and related conditions and deploy venture capital to invent, develop, and fuel solutions that address those needs.
AS FEATURED ON
